Ekso Bionics Holdings (Ekso Bionics Holdings) Cash And Cash Equivalents : $8.80 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Ekso Bionics Holdings Cash And Cash Equivalents?

Ekso Bionics Holdings's quarterly cash and cash equivalents declined from Sep. 2023 ($9.94 Mil) to Dec. 2023 ($8.64 Mil) but then increased from Dec. 2023 ($8.64 Mil) to Mar. 2024 ($8.80 Mil).

Ekso Bionics Holdings's annual cash and cash equivalents declined from Dec. 2021 ($40.41 Mil) to Dec. 2022 ($20.53 Mil) and declined from Dec. 2022 ($20.53 Mil) to Dec. 2023 ($8.64 Mil).

Ekso Bionics Holdings Cash And Cash Equivalents Historical Data

The historical data trend for Ekso Bionics Holdings's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ekso Bionics Holdings Cash And Cash Equivalents Chart

Ekso Bionics Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

10.87

12.86

40.41

20.53

8.64

Ekso Bionics Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															16.28	13.31	9.94	8.64	8.80

Ekso Bionics Holdings Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Ekso Bionics Holdings (NAS:EKSO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Ekso Bionics Holdings Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Ekso Bionics Holdings's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Ekso Bionics Holdings (Ekso Bionics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ekso Bionics Holdings Inc (NAS:EKSO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

23E2:Germany

Address

101 Glacier Point, Suite A, San Rafael, CA, USA, 94901

Website

https://www.eksobionics.com

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.

Executives

Jerome Wong	officer: Interim CFO	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Scott G. Davis	officer: President & COO	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Steven Sherman	director
Jason C Jones	officer: VP of Product Development	EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
John Glenn	officer: Chief Financial Officer	7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
Lathan Corinna	director	140 KENDRICK STREET, NEEDHAM MA 02494
William R Shaw	officer: See Remarks	1414 HARBOUR WAY SOUTH, SUITE 1201, C/O EKSO BIONICS HOLDINGS, INC., RICHMOND CA 94804
Rhonda A. Wallen	director	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Mary Ann Cloyd	director	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Combest Development (hong Kong) Ltd	10 percent owner	ROOM 2210, CC WU BUILDING 302, HENNESSY ROAD, WAN CHAI, HONG KONG K3 999077
Jack Peurach	director, officer: Chief Executive Officer	1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Thomas A Schreck	director	10240 BUBB RD, CUPERTINO CA 95014
Puissance Capital Management Lp	10 percent owner	950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Christian Babini	officer: VP of Sales, Americas	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1, RICHMOND CA 94804
Puissance Cross-border Opportunities Ii Llc	10 percent owner	C/O PUISSANCE CAPITAL FUND (GP) LLC, 950 THIRD AVENUE, NEW YORK NY 10022